Amgen’s Blincyto (Blinatumomab) Receives the US FDA’s Approval to Treat B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
Shots:
- The US FDA has granted approval to Blincyto (blinatumomab) in adult & pediatric patients (≥1mos. of age) with CD19+ Philadelphia chromosome-ve B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, irrespective of MRD status
- The approval was supported by the P-III (E1910) study, sponsored by ECOG-ACRIN Cancer Research Group, assessing Blincyto + CT vs CT alone in newly diagnosed Philadelphia chromosome-ve B-ALL patients on postinduction consolidation treatment to reach durable responses
- The study depicted 3yr. OS of 84.8% vs 69% (n=112 in each arm); 5yr. OS of 82.4% vs 62.5%, with median follow-up of 4.5yrs.
Ref: BeiGene | Image: BeiGene
Related News:- BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
